Rapid and early virological response to chronic hepatitis C treatment with IFN α2b or PEG-IFN α2b plus ribavirin in HIV/HCV co-infected patients

Gut

Volumn 56, Issue 8, 2007, Pages 1111-1116

  Payan, Christopher ^b   Pivert, Adeline ^a   Morand, Patrice ^c   Fafi Kremer, Samira ^c   Carrat, Fabrice ^d   Pol, Stanislas ^e   Cacoub, Patrice ^f   Perronne, Christian ^g   Lunel, Françoise ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BREST   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

^e Université René Descartes ^*  (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ALGORITHM; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SUPERINFECTION; TREATMENT OUTCOME; VIROLOGY;

ALGORITHMS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; ROC CURVE; TREATMENT OUTCOME;

EID: 34547173109     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.106690     Document Type: Article

References (23)

1. Lauer G, Walker B. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
2. Pol S, Vallet-Pichard A, Fontaine H. Hepatitis C and HIV co-infection at the era of HAART. J Viral Hepat 2002;9:1-8.
3. Cacoub P, Geffray L, Rosenthal E, for the Joint Study Group on Hepatitis C Virus of the French National Society of Internal Medicine and the French Society of Infectious Diseases (GERMIVIC Study Group), et al. Mortality among HIV-infected patients with cirrhosis or hepatocellular carcinoma due to HCV in French departments of internal medicine/infectious diseases, in 1995 and 1997. Clin Infect Dis 2001;32:1207-14.
4. Fialaire P, Payan C, Vitour D, et al. Sustained disappearance of Hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. J Infect Dis 1999;180:574-5.
5. Carrot F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b versus standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-48.
6. Torriani FJ, Rodriguez-Torres M, Rockstroh J, et al. PEG-interferon alfa-2a plus ribavirin for chronic HCV infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
7. Chung R, Andersen J, Volberding P, et al. Pegylated interferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV co-infected persons. N Engl J Med 2004;351:451-9.
8. Manns MP, McHutchison J, Gordon SC, et al. Peginterferon α2b plus ribavirin compared with interferon α2b plus ribavirin for initial treatment or chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
9. Fried M, Shiffman M, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
10. Davis G, Wong J, McHutchison J, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
11. Berg T, Sarrazin C, Herrman E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003;37:600-9.
12. McHutchison J, Blatt L, Sedghi-Vaziri A, et al. Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection? J Hepatol 1998;29:362-8.
13. Poynard T, Marcellin P, Lee S, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
14. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. The 2002 French consensus. Gut 2003;52:1784-7.
15. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C. Hepatology 2002;36:S3-20.
16. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005;42:615-24.
17. Zeuzem S, Schmidt J, Lee JH, et al. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alpha on viral turnover. Hepatology 1998;28:245-52.
18. Lunel F, Cresta P, Vitour D, et al. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and Monitor assays. Hepatology 1999;29:528-35.
19. Poynard T, McHutchison J, Goodman Z, et al. Is an «à la carte» combination interferon α2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis? Hepatology 2000;31:211-18.
20. Castro F, Esteban J, Juarez A, et al. Early detection of non response to interferon plus ribavirin combination treatment of chronic hepatitis C. J Viral Hepat 2002;9:202-7.
21. Ebeling F, Lappalainen M, Vuoristo M, et al. Factors predicting interferon treatment response in patients with chronic hepatitis C: late viral clearance does not preclude a sustained response. Am J Gastroenterol 2001;96:1237-42.
22. Sanchez-Tapias J, Diago M, Escartin M, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006;131:451-60.
23. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-97.